Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Envedotin (DP303c) vs Standard of Care in HER2+ Advanced Breast Cancer
NCT05901935Phase 3Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 3, randomised, open-label trial of DP303c in HER2-positive breast cancer (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Progression-free survival up to 5 years. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
DP303c
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05901935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901935.